Effective prophylaxis and treatment of thromboembolic events remain suboptimal in many healthcare systems, partly owing to limitations of traditional anticoagulants. New oral anticoagulants such as rivaroxaban, apixaban , and dabigatran etexilate have recently been developed. This article will compare the efficacy of this new triad with existing standard of care.
Warfarin, a vitamin K antagonist, has been the gold standard of care for over 50 years for the treatment or prevention blood clots in veins or arteries, which can reduce the risk of stroke, heart attack, or other serious conditions. The Recent advent of three molecules namely Dabigatran (direct thrombin inhibitor), rivaroxaban (Factor Xa inhibitor), and apixaban (Factor Xa inhibitor), the use of warfarin or low molecular weight heparin called enoxaparin is compared with above mentioned Target Specific Oral Anticoagulants…
